Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes

Ikwunga Wonodi, O. Colin Stine, Korrapati V. Sathyasaikumar, Rosalinda C. Roberts, Braxton D. Mitchell, L. Elliot Hong, Yasushi Kajii, Gunvant K. Thaker, Robert Schwarcz

Research output: Contribution to journalArticle

Abstract

Context: Kynurenic acid, a metabolite of the kynurenine pathway of tryptophan degradation, is an antagonist at N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors and modulates glutamate, dopamine, and acetylcholine signaling. Cortical kynurenic acid concentrations are elevated in the brain and cerebrospinal fluid of schizophrenia patients. The proximal cause may be an impairment of kynurenine 3-monooxygenase (KMO), a rate-limiting enzyme at the branching point of the kynurenine pathway. Objectives: To examine KMO messenger RNA expression and KMO enzyme activity in postmortem tissue from the frontal eye field (FEF; Brodmann area 6) obtained from schizophrenia individuals compared with healthy control individuals and to explore the relationship between KMO single-nucleotide polymorphisms and schizophrenia oculomotor endophenotypes. Design: Case-control postmortem and clinical study. Setting: Maryland Brain Collection, outpatient clinics. Participants: Postmortem specimens from schizophrenia patients (n=32) and control donors (n=32) and a clinical sample of schizophrenia patients (n=248) and healthy controls (n=228). Main Outcome Measures: Comparison of quantitative KMO messenger RNA expression and KMO enzyme activity in postmortem FEF tissue between schizophrenia patients and controls and association of KMO singlenucleotide polymorphisms with messenger RNA expression in postmortem FEF and schizophrenia and oculomotor endophenotypes (ie, smooth pursuit eye movements and oculomotor delayed response). Results: In postmortem tissue, we found a significant and correlated reduction in KMO gene expression and KMO enzyme activity in the FEF in schizophrenia patients. In the clinical sample, KMO rs2275163 was not associated with a diagnosis of schizophrenia but showed modest effects on predictive pursuit and visuospatial working memory endophenotypes. Conclusion: Our results provide converging lines of evidence implicating reduced KMO activity in the etiopathophysiology of schizophrenia and related neurocognitive deficits.

Original languageEnglish (US)
Pages (from-to)665-674
Number of pages10
JournalArchives of General Psychiatry
Volume68
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Kynurenine 3-Monooxygenase
Endophenotypes
Schizophrenia
Down-Regulation
Gene Expression
Enzymes
Kynurenic Acid
Kynurenine
Messenger RNA
1,4-alpha-Glucan Branching Enzyme
Smooth Pursuit
Brain
Nicotinic Receptors
Frontal Lobe
N-Methylaspartate
Eye Movements
Ambulatory Care Facilities
Short-Term Memory
Tryptophan

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. / Wonodi, Ikwunga; Stine, O. Colin; Sathyasaikumar, Korrapati V.; Roberts, Rosalinda C.; Mitchell, Braxton D.; Hong, L. Elliot; Kajii, Yasushi; Thaker, Gunvant K.; Schwarcz, Robert.

In: Archives of General Psychiatry, Vol. 68, No. 7, 07.2011, p. 665-674.

Research output: Contribution to journalArticle

Wonodi, I, Stine, OC, Sathyasaikumar, KV, Roberts, RC, Mitchell, BD, Hong, LE, Kajii, Y, Thaker, GK & Schwarcz, R 2011, 'Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes', Archives of General Psychiatry, vol. 68, no. 7, pp. 665-674. https://doi.org/10.1001/archgenpsychiatry.2011.71
Wonodi, Ikwunga ; Stine, O. Colin ; Sathyasaikumar, Korrapati V. ; Roberts, Rosalinda C. ; Mitchell, Braxton D. ; Hong, L. Elliot ; Kajii, Yasushi ; Thaker, Gunvant K. ; Schwarcz, Robert. / Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. In: Archives of General Psychiatry. 2011 ; Vol. 68, No. 7. pp. 665-674.
@article{e234375dd6cf4720b0c0118b5f1e5cca,
title = "Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes",
abstract = "Context: Kynurenic acid, a metabolite of the kynurenine pathway of tryptophan degradation, is an antagonist at N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors and modulates glutamate, dopamine, and acetylcholine signaling. Cortical kynurenic acid concentrations are elevated in the brain and cerebrospinal fluid of schizophrenia patients. The proximal cause may be an impairment of kynurenine 3-monooxygenase (KMO), a rate-limiting enzyme at the branching point of the kynurenine pathway. Objectives: To examine KMO messenger RNA expression and KMO enzyme activity in postmortem tissue from the frontal eye field (FEF; Brodmann area 6) obtained from schizophrenia individuals compared with healthy control individuals and to explore the relationship between KMO single-nucleotide polymorphisms and schizophrenia oculomotor endophenotypes. Design: Case-control postmortem and clinical study. Setting: Maryland Brain Collection, outpatient clinics. Participants: Postmortem specimens from schizophrenia patients (n=32) and control donors (n=32) and a clinical sample of schizophrenia patients (n=248) and healthy controls (n=228). Main Outcome Measures: Comparison of quantitative KMO messenger RNA expression and KMO enzyme activity in postmortem FEF tissue between schizophrenia patients and controls and association of KMO singlenucleotide polymorphisms with messenger RNA expression in postmortem FEF and schizophrenia and oculomotor endophenotypes (ie, smooth pursuit eye movements and oculomotor delayed response). Results: In postmortem tissue, we found a significant and correlated reduction in KMO gene expression and KMO enzyme activity in the FEF in schizophrenia patients. In the clinical sample, KMO rs2275163 was not associated with a diagnosis of schizophrenia but showed modest effects on predictive pursuit and visuospatial working memory endophenotypes. Conclusion: Our results provide converging lines of evidence implicating reduced KMO activity in the etiopathophysiology of schizophrenia and related neurocognitive deficits.",
author = "Ikwunga Wonodi and Stine, {O. Colin} and Sathyasaikumar, {Korrapati V.} and Roberts, {Rosalinda C.} and Mitchell, {Braxton D.} and Hong, {L. Elliot} and Yasushi Kajii and Thaker, {Gunvant K.} and Robert Schwarcz",
year = "2011",
month = "7",
doi = "10.1001/archgenpsychiatry.2011.71",
language = "English (US)",
volume = "68",
pages = "665--674",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes

AU - Wonodi, Ikwunga

AU - Stine, O. Colin

AU - Sathyasaikumar, Korrapati V.

AU - Roberts, Rosalinda C.

AU - Mitchell, Braxton D.

AU - Hong, L. Elliot

AU - Kajii, Yasushi

AU - Thaker, Gunvant K.

AU - Schwarcz, Robert

PY - 2011/7

Y1 - 2011/7

N2 - Context: Kynurenic acid, a metabolite of the kynurenine pathway of tryptophan degradation, is an antagonist at N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors and modulates glutamate, dopamine, and acetylcholine signaling. Cortical kynurenic acid concentrations are elevated in the brain and cerebrospinal fluid of schizophrenia patients. The proximal cause may be an impairment of kynurenine 3-monooxygenase (KMO), a rate-limiting enzyme at the branching point of the kynurenine pathway. Objectives: To examine KMO messenger RNA expression and KMO enzyme activity in postmortem tissue from the frontal eye field (FEF; Brodmann area 6) obtained from schizophrenia individuals compared with healthy control individuals and to explore the relationship between KMO single-nucleotide polymorphisms and schizophrenia oculomotor endophenotypes. Design: Case-control postmortem and clinical study. Setting: Maryland Brain Collection, outpatient clinics. Participants: Postmortem specimens from schizophrenia patients (n=32) and control donors (n=32) and a clinical sample of schizophrenia patients (n=248) and healthy controls (n=228). Main Outcome Measures: Comparison of quantitative KMO messenger RNA expression and KMO enzyme activity in postmortem FEF tissue between schizophrenia patients and controls and association of KMO singlenucleotide polymorphisms with messenger RNA expression in postmortem FEF and schizophrenia and oculomotor endophenotypes (ie, smooth pursuit eye movements and oculomotor delayed response). Results: In postmortem tissue, we found a significant and correlated reduction in KMO gene expression and KMO enzyme activity in the FEF in schizophrenia patients. In the clinical sample, KMO rs2275163 was not associated with a diagnosis of schizophrenia but showed modest effects on predictive pursuit and visuospatial working memory endophenotypes. Conclusion: Our results provide converging lines of evidence implicating reduced KMO activity in the etiopathophysiology of schizophrenia and related neurocognitive deficits.

AB - Context: Kynurenic acid, a metabolite of the kynurenine pathway of tryptophan degradation, is an antagonist at N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors and modulates glutamate, dopamine, and acetylcholine signaling. Cortical kynurenic acid concentrations are elevated in the brain and cerebrospinal fluid of schizophrenia patients. The proximal cause may be an impairment of kynurenine 3-monooxygenase (KMO), a rate-limiting enzyme at the branching point of the kynurenine pathway. Objectives: To examine KMO messenger RNA expression and KMO enzyme activity in postmortem tissue from the frontal eye field (FEF; Brodmann area 6) obtained from schizophrenia individuals compared with healthy control individuals and to explore the relationship between KMO single-nucleotide polymorphisms and schizophrenia oculomotor endophenotypes. Design: Case-control postmortem and clinical study. Setting: Maryland Brain Collection, outpatient clinics. Participants: Postmortem specimens from schizophrenia patients (n=32) and control donors (n=32) and a clinical sample of schizophrenia patients (n=248) and healthy controls (n=228). Main Outcome Measures: Comparison of quantitative KMO messenger RNA expression and KMO enzyme activity in postmortem FEF tissue between schizophrenia patients and controls and association of KMO singlenucleotide polymorphisms with messenger RNA expression in postmortem FEF and schizophrenia and oculomotor endophenotypes (ie, smooth pursuit eye movements and oculomotor delayed response). Results: In postmortem tissue, we found a significant and correlated reduction in KMO gene expression and KMO enzyme activity in the FEF in schizophrenia patients. In the clinical sample, KMO rs2275163 was not associated with a diagnosis of schizophrenia but showed modest effects on predictive pursuit and visuospatial working memory endophenotypes. Conclusion: Our results provide converging lines of evidence implicating reduced KMO activity in the etiopathophysiology of schizophrenia and related neurocognitive deficits.

UR - http://www.scopus.com/inward/record.url?scp=79960312085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960312085&partnerID=8YFLogxK

U2 - 10.1001/archgenpsychiatry.2011.71

DO - 10.1001/archgenpsychiatry.2011.71

M3 - Article

C2 - 21727251

AN - SCOPUS:79960312085

VL - 68

SP - 665

EP - 674

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 7

ER -